RESUMO
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the 2019 coronavirus disease (COVID-19) pandemic, have been rapidly developed and authorized. However, re-cent studies showed that COVID-19 vaccination is associated with a wide range of dermatological reactions. The most prevalent adverse dermatological reaction observed in observational studies was a delayed large lo-cal reaction (DLRs), which is characterized by the appearance of an erythematous and edematous patch at the injection site four days or more after vaccination. Most of these reactions are common in females and resolve spontaneously within a few days to a weak. The second dose of the vaccine was associated with a higher inci-dence of cutaneous reactions compared to the first dose but milder in intensity. It seems that the Moderna vaccine is associated with a higher incidence of these adverse events compared to the Pfizer vaccine. Fur-thermore, mRNA vaccines had a higher incidence than vector-based and inactivated vaccines. There is a lack of evidence regarding the side events of the Johnson & Janssen vaccine. Further long-term, multicenter studies are required to compare these vaccines and highlight the best practice in managing these reactions.
RESUMO
Background: the incidence of depression in vitiligo patients ranges from 10% to over 60%, depending on the outcome measures, sample size and study population. The purpose is to estimate the prevalence of depression among vitiligo patients by conducting a systematic review and metanalysis of published studies. Methods: we conducted a literature search on Medline via PubMed, Scopus, web of science and Cochrane library. Results: 35 studies finally met our inclusion criteria. Our findings showed that the overall prevalence of depression among patients with vitiligo was 35 % (26%-45). Moreover, we observed a variation in the prevalence based on the used tool. For example, the GHQ revealed 30% (20%-39%) and the HDRS re-vealed 50% (44% - 57%). Our analysis demonstrated no significant differences between vitiligo and healthy cases in terms of HDRS and DBI. Moreover, there was no significant differences between vitiligo and psoriasis in terms of GHQ and BDI scores. Conclusion: in conclusion the current evidence suggests that patients with vitiligo have a high risk and prevalence of depression, different questionnaires have yielded variable prevalence due to the different domains and validation method.